<DOC>
	<DOCNO>NCT02525471</DOCNO>
	<brief_summary>The purpose study determine safety tolerability RNS60 patient Amyotrophic lateral sclerosis ( ALS ) . Investigators also measure impact RNS60 several marker neuro-inflammation , measure blood biomarkers positron emission tomography ( PET ) imaging .</brief_summary>
	<brief_title>A Pilot Study RNS60 Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description>Amyotrophic lateral sclerosis ( ALS ) fatal , neurodegenerative disease cure . A substantial body evidence implicate neuroimmune system ALS pathophysiology . Of relevance study , microglia activation brain find correlate positively faster rate disease progression . In addition , study blood cell people ALS show increased activation two major inflammatory cell type body , monocytes T cell . Among T cell , regulatory T cell ( Tregs ) recently propose play role ALS progression . RNS60 electrokinetically alter aqueous fluid . Chemically , RNS60 compose saline oxygen . The electrokinetic processing RNS60 Revalesio 's patented Revalesio Pump ( RP ) produce charge-stabilized nanostructures ( CSNs ) exhibit electrical field . RNS60 available intravenous administration inhalation . RNS60 extensively test preclinical toxicological study show little side effect . In addition , RNS60 well tolerate three phase I human safety study , one intravenous administration two inhalation . Preclinical vitro vivo study multiple disease model demonstrate RNS60 broad anti-inflammatory effect . These effect include reduction microglia activation , increase Tregs subpopulation lymphocyte , neuroprotection several disease model .</detailed_description>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Amyotrophic Lateral Sclerosis ( ALS ) volunteer must diagnose possible , probable , probablelaboratory support , definite ALS , either sporadic familial accord modify El Escorial criterion . Age 1880 , able provide inform consent , comply study procedure . Participants must take riluzole least 30 day , stable dose riluzole least 30 day , prior screening ( riluzolena√Øve participant permit study ) . Women must able become pregnant ( e.g . post menopausal , surgically sterile , use adequate birth control ) duration study 3 month study completion . Males practice contraception duration study 3 month completion . Ability safely lie flat 90 min Positron Emission Tomography ( PET ) procedures opinion study physician . High mixed affinity bind translocator ( TSPO ) protein ( Ala/Ala Ala/Thr ) Abnormal liver function define aspartate aminotransferase ( AST ) and/or alanine transaminase ( ALT ) &gt; 3 time upper limit normal . Renal insufficiency define serum creatinine &gt; 1.5 time upper limit normal . The presence unstable psychiatric disease , cognitive impairment , dementia would impair ability participant provide inform consent , accord PI judgment . Clinically significant unstable medical condition ( ALS ) would pose risk participant participate study . History HIV , clinically significant chronic hepatitis , active infection . Females must lactate pregnant . Active participation another ALS clinical trial within 30 day Screening Visit Exposure immunomodulatory medication within 30 day Screening Visit . Any contraindication undergo MRI study History cardiac pacemaker pacemaker wire Metallic particle body Vascular clip head Prosthetic heart valve Claustrophobia Radiation exposure exceed site 's current guideline Current use tobacco product include cigarette , cigar , snuff chew tobacco , nicotine replacement product gum patch</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>